131 related articles for article (PubMed ID: 33416145)
1. Targeting eIF4A using rocaglate CR‑1‑31B sensitizes gallbladder cancer cells to TRAIL‑mediated apoptosis through the translational downregulation of c‑FLIP.
Cao Y; He Y; Yang L; Luan Z
Oncol Rep; 2021 Jan; 45(1):230-238. PubMed ID: 33416145
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of c‑FLIP and upregulation of DR‑5 by cantharidin sensitizes TRAIL‑mediated apoptosis in prostate cancer cells via autophagy flux.
Nazim UM; Yin H; Park SY
Int J Mol Med; 2020 Jul; 46(1):280-288. PubMed ID: 32319535
[TBL] [Abstract][Full Text] [Related]
3. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.
Luan Z; He Y; He F; Chen Z
Mol Med Rep; 2015 Jan; 11(1):203-11. PubMed ID: 25333816
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
5. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.
Murtaza I; Saleem M; Adhami VM; Hafeez BB; Mukhtar H
Cancer Res; 2009 Feb; 69(3):1156-65. PubMed ID: 19176377
[TBL] [Abstract][Full Text] [Related]
6. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
Zhu W; Zhan D; Wang L; Ma D; Cheng M; Wang H; Zhao J; Cai Y; Cheng Z
Oncol Rep; 2016 Aug; 36(2):845-52. PubMed ID: 27277541
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-mediated upregulation of DR5 and downregulation of cFLIP synergistically sensitize HeLa cells to TRAIL-mediated apoptosis.
Poondla N; Chandrasekaran AP; Heese K; Kim KS; Ramakrishna S
Biochem Biophys Res Commun; 2019 Apr; 512(1):60-65. PubMed ID: 30862357
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase interference synergistically promotes tumor necrosis factor‑related apoptosis‑inducing ligand‑induced oral squamous cell carcinoma apoptosis and suppresses proliferation in vitro and in vivo.
Zhao X; Zhang C; Le Z; Zeng S; Pan C; Shi J; Wang J; Zhao X
Int J Mol Med; 2018 Sep; 42(3):1283-1294. PubMed ID: 29901096
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of circSMAD2 inhibits the tumorigenesis of gallbladder cancer through binding with eIF4A3.
Qin Y; Zheng Y; Huang C; Li Y; Gu M; Wu Q
BMC Cancer; 2021 Nov; 21(1):1172. PubMed ID: 34727877
[TBL] [Abstract][Full Text] [Related]
11. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs.
Nalli AD; Brown LE; Thomas CL; Sayers TJ; Porco JA; Henrich CJ
Sci Rep; 2018 Nov; 8(1):17519. PubMed ID: 30504817
[TBL] [Abstract][Full Text] [Related]
13. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
14. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma.
Zong H; Yin B; Chen J; Ma B; Cai D; He X
Tohoku J Exp Med; 2009 Mar; 217(3):203-8. PubMed ID: 19282655
[TBL] [Abstract][Full Text] [Related]
16. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes.
Wachter T; Sprick M; Hausmann D; Kerstan A; McPherson K; Stassi G; Bröcker EB; Walczak H; Leverkus M
J Biol Chem; 2004 Dec; 279(51):52824-34. PubMed ID: 15459191
[TBL] [Abstract][Full Text] [Related]
17. Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines.
Park EJ; Kim HD; Choi EK; Hoe KL; Kim DU
Biochem Biophys Res Commun; 2020 Dec; 533(3):289-295. PubMed ID: 32958259
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.
Clarke P; Tyler KL
Apoptosis; 2007 Jan; 12(1):211-23. PubMed ID: 17136319
[TBL] [Abstract][Full Text] [Related]
19. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Zhang T; Wang X; He D; Jin X; Guo P
Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
[TBL] [Abstract][Full Text] [Related]
20. Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.
Yang L; Wang Q; Li D; Zhou Y; Zheng X; Sun H; Yan J; Zhang L; Lin Y; Wang X
Apoptosis; 2013 May; 18(5):618-26. PubMed ID: 23371323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
